277 related articles for article (PubMed ID: 33435632)
1. Signaling Pathway Mediating Myeloma Cell Growth and Survival.
Hideshima T; Anderson KC
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33435632
[TBL] [Abstract][Full Text] [Related]
2. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.
Hayashi T; Hideshima T; Nguyen AN; Munoz O; Podar K; Hamasaki M; Ishitsuka K; Yasui H; Richardson P; Chakravarty S; Murphy A; Chauhan D; Higgins LS; Anderson KC
Clin Cancer Res; 2004 Nov; 10(22):7540-6. PubMed ID: 15569984
[TBL] [Abstract][Full Text] [Related]
3. Growth factors and antiapoptotic signaling pathways in multiple myeloma.
van de Donk NW; Lokhorst HM; Bloem AC
Leukemia; 2005 Dec; 19(12):2177-85. PubMed ID: 16239913
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment.
Hayashi T; Hideshima T; Akiyama M; Richardson P; Schlossman RL; Chauhan D; Munshi NC; Waxman S; Anderson KC
Mol Cancer Ther; 2002 Aug; 1(10):851-60. PubMed ID: 12492118
[TBL] [Abstract][Full Text] [Related]
5. Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma.
Ria R; Vacca A
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963513
[TBL] [Abstract][Full Text] [Related]
6. Identification and validation of novel therapeutic targets for multiple myeloma.
Hideshima T; Chauhan D; Richardson P; Anderson KC
J Clin Oncol; 2005 Sep; 23(26):6345-50. PubMed ID: 16155018
[TBL] [Abstract][Full Text] [Related]
7. Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma.
Neri P; Bahlis NJ
Curr Cancer Drug Targets; 2012 Sep; 12(7):776-96. PubMed ID: 22671924
[TBL] [Abstract][Full Text] [Related]
8. Targeting multiple myeloma cells and their bone marrow microenvironment.
Pagnucco G; Cardinale G; Gervasi F
Ann N Y Acad Sci; 2004 Dec; 1028():390-9. PubMed ID: 15650264
[TBL] [Abstract][Full Text] [Related]
9. HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.
Borsi E; Perrone G; Terragna C; Martello M; Zamagni E; Tacchetti P; Pantani L; Brioli A; Dico AF; Zannetti BA; Rocchi S; Cavo M
Exp Cell Res; 2014 Nov; 328(2):444-55. PubMed ID: 25257607
[TBL] [Abstract][Full Text] [Related]
10. The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.
Wang J; De Veirman K; De Beule N; Maes K; De Bruyne E; Van Valckenborgh E; Vanderkerken K; Menu E
Oncotarget; 2015 Dec; 6(41):43992-4004. PubMed ID: 26556857
[TBL] [Abstract][Full Text] [Related]
11. Integrin alpha4beta1 involvement in stromal cell-derived factor-1alpha-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion.
Parmo-Cabañas M; Bartolomé RA; Wright N; Hidalgo A; Drager AM; Teixidó J
Exp Cell Res; 2004 Apr; 294(2):571-80. PubMed ID: 15023543
[TBL] [Abstract][Full Text] [Related]
12. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
[TBL] [Abstract][Full Text] [Related]
13. The malignant clone and the bone-marrow environment.
Podar K; Richardson PG; Hideshima T; Chauhan D; Anderson KC
Best Pract Res Clin Haematol; 2007 Dec; 20(4):597-612. PubMed ID: 18070708
[TBL] [Abstract][Full Text] [Related]
14. Role of the bone marrow microenvironment in multiple myeloma.
Roodman GD
J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
[TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment.
Corso A; Ferretti E; Lazzarino M
Hematology; 2005 Jun; 10(3):215-24. PubMed ID: 16019470
[TBL] [Abstract][Full Text] [Related]
16. Cytokines and signal transduction.
Hideshima T; Podar K; Chauhan D; Anderson KC
Best Pract Res Clin Haematol; 2005; 18(4):509-24. PubMed ID: 16026734
[TBL] [Abstract][Full Text] [Related]
17. Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential.
Spaan I; Raymakers RA; van de Stolpe A; Peperzak V
J Hematol Oncol; 2018 May; 11(1):67. PubMed ID: 29776381
[TBL] [Abstract][Full Text] [Related]
18. Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche.
Colombo M; Galletti S; Bulfamante G; Falleni M; Tosi D; Todoerti K; Lazzari E; Crews LA; Jamieson CH; Ravaioli S; Baccianti F; Garavelli S; Platonova N; Neri A; Chiaramonte R
Oncotarget; 2016 Aug; 7(35):56013-56029. PubMed ID: 27463014
[TBL] [Abstract][Full Text] [Related]
19. Migration, adhesion and differentiation of malignant plasma cells in the 5T murine model of myeloma.
Asosingh K
Verh K Acad Geneeskd Belg; 2003; 65(2):127-34. PubMed ID: 12870183
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
Görgün G; Samur MK; Cowens KB; Paula S; Bianchi G; Anderson JE; White RE; Singh A; Ohguchi H; Suzuki R; Kikuchi S; Harada T; Hideshima T; Tai YT; Laubach JP; Raje N; Magrangeas F; Minvielle S; Avet-Loiseau H; Munshi NC; Dorfman DM; Richardson PG; Anderson KC
Clin Cancer Res; 2015 Oct; 21(20):4607-18. PubMed ID: 25979485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
